• Spotlight on

Life sciences supply chain resilience outlook

The life sciences supply chain has entered a new era of complexity. Drug shortages, manufacturing disruptions, and logistics constraints remain persistent challenges, but the forces driving them have shifted. Disruption is no longer isolated to a single factory or supplier. It now reflects a convergence of regulatory, geopolitical, cyber, and climate risks that can ripple across multiple tiers at once, slowing production and limiting patient access to essential medicines.

This spotlight report uses exclusive disruption data and year-over-year trends to show where life sciences supply chains are most exposed and what leaders can do about it. It covers the top sources of disruption, implications for manufacturing and supplier strategy, and practical steps to build resilience before the next crisis hits.

Key takeaways

Systemic complexity is redefining supply chain resilience

14,841 life sciences disruption alerts and a 30% YoY increase point to sustained pressure on supply continuity

Disruption exposure is increasingly cross-functional, with labor, climate, and cyber risks affecting production, release timing, and logistics at once

Resilience performance now depends on faster detection, tighter partner coordination, and fewer single points of failure across the network